Abstract 339: Hospitalization Rates and Healthcare Costs Among Non-valvular Atrial Fibrillation Patients Who Were Naive Users of Novel Oral Anticoagulants [Session Title: Poster Session III]
Conclusions: This early assessment shows that among anticoagulant naïve NVAF patients, treatment with apixaban was associated with a lower rate of all-cause hospitalization, as well as lower overall costs compared to other NOACs. Further evaluation is needed to provide additional detail on potential drivers of utilization differences.
Source: Circulation: Cardiovascular Quality and Outcomes - Category: Cardiology Authors: Deitelzweig, S., Bruno, A., Tate, N., Ogbonnaya, A., Shah, M., Farrelly, E., Lokhandwala, T., Gupta, K., Eaddy, M. Tags: Session Title: Poster Session III Source Type: research
More News: Atrial Fibrillation | Cardiology | Cardiovascular | Clinical Trials | Healthcare Costs | Heart | Pradaxa | Stroke | Study